ArticleFrontiers in public health2026
Preferences of people living with HIV for treatment regimen attributes: a qualitative interview study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To develop effective HIV treatments, including long-acting injectables, understanding the treatment attributes and personal factors that are significant to people living with HIV is essential. Methods: We conducted individual qualitative interviews with people living with HIV and healthcare providers (HCP) in the United States to evaluate treatment preferences if considering a hypothetical treatment switch. We performed a targeted literature review and identified five attributes related to HIV treatment: (1) administration mode, (2) administration setting, (3) administration frequency, (4) location of injection on the body, and (5) side effects. We also recorded any spontaneously mentioned attributes and other factors influencing treatment decisions. A thematic analysis was conducted using MAXQDA, with dual independent coding of 20% of transcripts and third-party reconciliation by the qualitative lead. Spanish-language transcripts were reviewed in both the original and translated versions to preserve meaning. Results: We interviewed 50 people living with HIV and 5 HCPs. Among people living with HIV, 60% were male, 62% had no prior injection treatment experience, and median (interquartile range) age was 50 (39.8-55.8) years. Side effects emerged as the highest priority attribute for people living with HIV and for HCPs, followed by administration frequency and mode. Most participants expressed a clear preference for injectable over oral administration when all injection forms (intramuscular, subcutaneous, intravenous, combinations) were considered together. Among HCP-administered injection options, 4- and 6-month intervals were widely preferred, driven by alignment with existing appointment schedules and relationships with providers. Conclusion: When considering treatment options, the highest priorities for people living with HIV are reducing side effects and administration frequency. A planned quantitative discrete choice experiment will evaluate generalizability of our results and provide evidence to support stakeholder decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.